Pekin Hardy Strauss Inc. acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 54,050 shares of the company’s stock, valued at approximately $571,000.
Several other hedge funds also recently modified their holdings of ROIV. Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 81.0% in the 4th quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $213,370,000 after acquiring an additional 8,500,000 shares in the last quarter. Norges Bank bought a new position in Roivant Sciences during the fourth quarter worth about $41,506,000. First Trust Advisors LP grew its holdings in Roivant Sciences by 434.8% during the fourth quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock worth $30,764,000 after purchasing an additional 2,227,192 shares during the period. Penn Davis Mcfarland Inc. bought a new position in Roivant Sciences during the first quarter worth about $17,287,000. Finally, BlackBarn Capital Partners LP bought a new position in Roivant Sciences during the fourth quarter worth about $17,406,000. Institutional investors own 64.76% of the company’s stock.
Roivant Sciences Stock Up 0.1 %
NASDAQ ROIV opened at $12.05 on Wednesday. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences Ltd. has a 1-year low of $8.24 and a 1-year high of $13.24. The company has a 50 day moving average of $11.42 and a 200-day moving average of $11.04. The company has a market cap of $8.90 billion, a price-to-earnings ratio of 2.38 and a beta of 1.25.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on ROIV. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Monday, September 9th. Piper Sandler lifted their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.15.
View Our Latest Research Report on ROIV
Roivant Sciences Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
- Five stocks we like better than Roivant Sciences
- How to Invest in Small Cap StocksĀ
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Insider Trades May Not Tell You What You Think
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- 3 Stocks to Consider Buying in October
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.